Blue­bird hopes to raise up­wards of $100M by sell­ing shares

3 years ago
Financing

J&J re­ports sec­ond HIV vac­cine reg­i­men fail­ure in 18 months

3 years ago
R&D
Pharma

The con­fer­ence is back. What about the in­dus­try? Tak­ing the biotech pulse at #JPM23

3 years ago
Financing
In Focus

Ex-US Com­merce Sec­re­tary Wilbur Ross pairs his SPAC with Alzheimer's biotech

3 years ago
Startups
Deals

With CEO search, PhI­II study un­der­way, Ful­crum Ther­a­peu­tics rais­es $125M from stock of­fer­ing

3 years ago
Financing
R&D

Bank­rupt Phase­Bio set­tles with in­vestor-part­ner, hand­ing off late-stage drug

3 years ago
Deals
Law

Gene ther­a­py side ef­fects prompt search for new de­liv­ery meth­ods

3 years ago
R&D
Cell/Gene Tx

Ready to ex­pand, Gen­Script rais­es $224M for CD­MO fo­cused on an­ti­bod­ies, cell and gene ther­a­pies

3 years ago
Financing
China

Ak­ili cuts about 30% of staff in ef­fort to be 'ex­treme­ly lean'

3 years ago
People
Pharma

Mod­er­na jumps in­to piv­otal pack with promis­ing RSV da­ta as big ri­vals face off in megablock­buster race

3 years ago
R&D

ICER: Ma­jor­i­ty of pay­er cov­er­age poli­cies sup­port 'key el­e­ments of fair ac­cess' in for­mu­la­ries

3 years ago
Pharma

Pfiz­er inks deal to snatch Abzena's new North Car­oli­na man­u­fac­tur­ing site

3 years ago
Manufacturing

CMS ini­ti­ates cov­er­age analy­sis for provider-ad­min­is­tered PrEP to pre­vent HIV

3 years ago
Pharma

FDA of­fers new draft guid­ance on can­cer drug dose op­ti­miza­tion with over­haul of max­i­mum tol­er­at­ed dose par­a­digm

3 years ago
FDA+

PwC pre­dicts 'flur­ry' of $5B to $15B biotech deals in 2023

3 years ago
Deals
Pharma

Biden’s chief sci­ence of­fi­cer for Covid-19 steps down amid dearth of top lead­er­ship

3 years ago
FDA+

Drug name re­view: Sci­ence takes the spot­light in 2022

3 years ago
Pharma
Marketing

Aeter­na dis­con­tin­ues vac­cine de­vel­op­ment; Idera re­brands as Ac­er­a­gen

3 years ago
News Briefing

Pfiz­er shifts full port­fo­lio to non-prof­it mod­el in 45 low­er-in­come coun­tries

3 years ago
Pharma

Fol­low­ing Alzheimer’s drug ap­proval, an­a­lysts dish on what they ex­pect from Bio­gen in 2023 

3 years ago
Pharma

Mar­ket­ingRx roundup: Eli Lil­ly de­buts un­brand­ed ‘mem­o­ry’ is­sues TV ad; Big Phar­mas amp so­cial me­dia spend­ing

3 years ago
Pharma
Marketing

Leap Ther­a­peu­tics jumps in­to grow­ing Claudin18.2 field by buy­ing Flame Bio­sciences

3 years ago
Financing
Startups

NewAms­ter­dam notch­es an­oth­er win in res­ur­rec­tion of Am­gen car­dio drug

3 years ago
R&D

Ab­b­Vie, Eli Lil­ly quit UK's vol­un­tary drug pric­ing agree­ment, send­ing 'warn­ing sig­nal' to UK gov­ern­ment

3 years ago
Pharma
First page Previous page 401402403404405406407 Next page Last page
A service from the Financial Times